Contract win and contract extension
IXICO plc has secured new business and contract extensions valued at £1.3 million over two years, bolstering its position in neurological disorder research. The company will provide amyloid PET imaging analytics to validate a new Alzheimer's Disease blood-based biomarker test, aiming for FDA clearance, and has extended a Phase 2 Huntington's Disease clinical trial contract by adding three new analysis methodologies. These developments align with IXICO's growth strategy, deepening its impact in Alzheimer's and maintaining leadership in Huntington's disease research while advancing towards higher-value clinical development work.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
21 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug and diagnostics development in neurological disorders, today announced a contract win and contract extension with a total value of £1.3 million over 2 years.
Blood based biomarker validation contract
IXICO will provide amyloid PET imaging analytics to validate a new Alzheimer's Disease (AD) blood-based biomarker test for a global diagnostics and life sciences company with the aim of facilitating FDA regulatory clearance.
Phase 2 contract extension
This extends an existing Phase 2 Huntington's Disease (HD) clinical trial contract with a leading global pharmaceutical company, expanding the existing analysis methodologies with three additional analysis approaches.
Bram Goorden, Chief Executive Officer of IXICO, commented: "These latest contract wins are first and foremost important for progress in research and patient care. They also fit squarely in the growth strategy for our company, hitting three key components of the plan: deepening impact in broader CNS areas such as AD while maintaining leadership in rare neurodegenerative disease areas like HD, enabling novel modalities and moving toward high-value later stage clinical development work. It is deeply satisfying to see an increasing number of clients recognise IXICO's leading role in the field of CNS precision medicine".
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.